Switch to:
More From Other Websites
Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research... Mar 27 2017
Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research... Mar 27 2017
Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on... Mar 20 2017
Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on... Mar 20 2017
Companies Aiming for the Billion-Dollar Opioid Addiction Market Mar 18 2017
Alkermes Starts Phase III Study to Treat Multiple Sclerosis Mar 17 2017
Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of... Mar 16 2017
Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of... Mar 16 2017
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : March 14, 2017 Mar 14 2017
ALKERMES PLC. Files SEC form 8-K, Other Events Mar 10 2017
[video]The 'Gnarly 9' Biotechs Will Test the FDA's Mettle Mar 08 2017
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle Mar 08 2017
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 07 2017
Here’s What Mott Capital Management Thinks About Netflix, Alkermes, Vodafone & More Mar 02 2017
Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care... Feb 28 2017
Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care... Feb 28 2017
Drug Addiction Treatment Stocks to Watch Feb 22 2017
ALKERMES PLC. Financials Feb 22 2017
Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017 Feb 17 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK